Skip to main content
Premium Trial:

Request an Annual Quote

GVK Bio, Crelux Partner on Drug Discovery Platform

NEW YORK (GenomeWeb News) - GVK Biosciences is collaborating with Crelux to offer biopharmaceutical companies an integrated drug discovery and development platform for use in structure-based drug design programs, Hyderabad, India-based GVK Bio said today.

GVK Bio will conduct in silico, in vitro, and in vivo studies and functions related to preclinical candidate nomination, while Munich-based Crelux will perform multifaceted structural studies toward X-ray elucidation of fragment or lead target complexes.

GVK said that the integrated offering may be used in "all aspects of structure-based drug design" and it offers "accelerated timelines for moving molecules from concept into the clinic at an optimal cost."